Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

YM-222714

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
We investigated the effects of ketoconazole on the pharmacokinetics (PK) of the direct clotting factor Xa inhibitor darexaban… Expand
2013
2013
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
2013
2013
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand
2013
2013
BACKGROUND Darexaban is a potent direct factor Xa (FXa) inhibitor developed for prophylaxis of venous and arterial thromboembolic… Expand
2012
2012
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma… Expand
2011
2011
Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease… Expand
2011
2011
Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 5
2010
2010
Abstract 4393 Background: YM150, a potent oral direct factor Xa (FXa) inhibitor, is in development for the prevention of venous… Expand